nodes	percent_of_prediction	percent_of_DWPC	metapath
Cisatracurium Besylate—Hypoxemia—Gemcitabine—kidney cancer	0.0427	0.0443	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Everolimus—kidney cancer	0.024	0.0249	CcSEcCtD
Cisatracurium Besylate—Doxacurium chloride—BCHE—kidney cancer	0.019	0.515	CrCbGaD
Cisatracurium Besylate—Mivacurium—BCHE—kidney cancer	0.0178	0.485	CrCbGaD
Cisatracurium Besylate—Myopathy—Erlotinib—kidney cancer	0.0176	0.0183	CcSEcCtD
Cisatracurium Besylate—Azotaemia—Vincristine—kidney cancer	0.017	0.0176	CcSEcCtD
Cisatracurium Besylate—Myopathy—Sunitinib—kidney cancer	0.0152	0.0158	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Erlotinib—kidney cancer	0.014	0.0146	CcSEcCtD
Cisatracurium Besylate—Hypoxia—Gemcitabine—kidney cancer	0.0135	0.014	CcSEcCtD
Cisatracurium Besylate—Wheezing—Everolimus—kidney cancer	0.0124	0.0129	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Everolimus—kidney cancer	0.00883	0.00916	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Temsirolimus—kidney cancer	0.00848	0.00881	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Pazopanib—kidney cancer	0.00828	0.00859	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Everolimus—kidney cancer	0.00819	0.0085	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Pazopanib—kidney cancer	0.00799	0.0083	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Everolimus—kidney cancer	0.00789	0.00819	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Temsirolimus—kidney cancer	0.00783	0.00813	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Temsirolimus—kidney cancer	0.0078	0.00809	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Temsirolimus—kidney cancer	0.00778	0.00808	CcSEcCtD
Cisatracurium Besylate—Flushing—Pazopanib—kidney cancer	0.00755	0.00784	CcSEcCtD
Cisatracurium Besylate—Erythema—Temsirolimus—kidney cancer	0.00751	0.0078	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Pazopanib—kidney cancer	0.00738	0.00766	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Pazopanib—kidney cancer	0.00733	0.00761	CcSEcCtD
Cisatracurium Besylate—Erythema—Pazopanib—kidney cancer	0.00708	0.00735	CcSEcCtD
Cisatracurium Besylate—Wheezing—Paclitaxel—kidney cancer	0.00697	0.00723	CcSEcCtD
Cisatracurium Besylate—Angioedema—Temsirolimus—kidney cancer	0.00687	0.00713	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Sunitinib—kidney cancer	0.00684	0.0071	CcSEcCtD
Cisatracurium Besylate—Convulsion—Temsirolimus—kidney cancer	0.00651	0.00676	CcSEcCtD
Cisatracurium Besylate—Hypertension—Temsirolimus—kidney cancer	0.00649	0.00674	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Gemcitabine—kidney cancer	0.00643	0.00667	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Temsirolimus—kidney cancer	0.00635	0.0066	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Everolimus—kidney cancer	0.00631	0.00655	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Vincristine—kidney cancer	0.00623	0.00647	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Temsirolimus—kidney cancer	0.00613	0.00637	CcSEcCtD
Cisatracurium Besylate—Hypertension—Pazopanib—kidney cancer	0.00611	0.00635	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Erlotinib—kidney cancer	0.00609	0.00632	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Temsirolimus—kidney cancer	0.00601	0.00624	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Pazopanib—kidney cancer	0.00599	0.00621	CcSEcCtD
Cisatracurium Besylate—Flushing—Everolimus—kidney cancer	0.00596	0.00619	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Temsirolimus—kidney cancer	0.00596	0.00618	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Everolimus—kidney cancer	0.00583	0.00605	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Everolimus—kidney cancer	0.0058	0.00602	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Everolimus—kidney cancer	0.00579	0.00601	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Vincristine—kidney cancer	0.00578	0.006	CcSEcCtD
Cisatracurium Besylate—Injury—Paclitaxel—kidney cancer	0.00567	0.00588	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Pazopanib—kidney cancer	0.00567	0.00588	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Pazopanib—kidney cancer	0.00561	0.00583	CcSEcCtD
Cisatracurium Besylate—Erythema—Everolimus—kidney cancer	0.00559	0.0058	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Erlotinib—kidney cancer	0.00558	0.0058	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Sorafenib—kidney cancer	0.00548	0.00569	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Temsirolimus—kidney cancer	0.00547	0.00568	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Sunitinib—kidney cancer	0.00546	0.00567	CcSEcCtD
Cisatracurium Besylate—Erythema—Erlotinib—kidney cancer	0.00539	0.0056	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Gemcitabine—kidney cancer	0.00529	0.00549	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Sunitinib—kidney cancer	0.00527	0.00547	CcSEcCtD
Cisatracurium Besylate—Flushing—Sorafenib—kidney cancer	0.00517	0.00537	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Pazopanib—kidney cancer	0.00515	0.00535	CcSEcCtD
Cisatracurium Besylate—Angioedema—Everolimus—kidney cancer	0.00511	0.0053	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Sorafenib—kidney cancer	0.00506	0.00525	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Sorafenib—kidney cancer	0.00503	0.00523	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Sorafenib—kidney cancer	0.00502	0.00522	CcSEcCtD
Cisatracurium Besylate—Flushing—Sunitinib—kidney cancer	0.00498	0.00517	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Paclitaxel—kidney cancer	0.00495	0.00514	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Sunitinib—kidney cancer	0.00487	0.00505	CcSEcCtD
Cisatracurium Besylate—Convulsion—Vinblastine—kidney cancer	0.00486	0.00505	CcSEcCtD
Cisatracurium Besylate—Erythema—Sorafenib—kidney cancer	0.00485	0.00504	CcSEcCtD
Cisatracurium Besylate—Hypertension—Vinblastine—kidney cancer	0.00484	0.00503	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Sunitinib—kidney cancer	0.00484	0.00503	CcSEcCtD
Cisatracurium Besylate—Convulsion—Everolimus—kidney cancer	0.00484	0.00503	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Sunitinib—kidney cancer	0.00483	0.00502	CcSEcCtD
Cisatracurium Besylate—Hypertension—Everolimus—kidney cancer	0.00483	0.00501	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Everolimus—kidney cancer	0.00473	0.00491	CcSEcCtD
Cisatracurium Besylate—Flushing—Dactinomycin—kidney cancer	0.00471	0.00489	CcSEcCtD
Cisatracurium Besylate—Erythema—Sunitinib—kidney cancer	0.00467	0.00485	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Paclitaxel—kidney cancer	0.00459	0.00477	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Erlotinib—kidney cancer	0.00456	0.00473	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Temsirolimus—kidney cancer	0.00452	0.00469	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Everolimus—kidney cancer	0.00447	0.00464	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Vincristine—kidney cancer	0.00446	0.00463	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Everolimus—kidney cancer	0.00445	0.00462	CcSEcCtD
Cisatracurium Besylate—Angioedema—Sorafenib—kidney cancer	0.00443	0.0046	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Everolimus—kidney cancer	0.00443	0.0046	CcSEcCtD
Cisatracurium Besylate—Erythema—Dactinomycin—kidney cancer	0.00442	0.00459	CcSEcCtD
Cisatracurium Besylate—Pruritus—Temsirolimus—kidney cancer	0.00434	0.0045	CcSEcCtD
Cisatracurium Besylate—Cardiovascular disorder—Doxorubicin—kidney cancer	0.00432	0.00448	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Erlotinib—kidney cancer	0.00432	0.00448	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Erlotinib—kidney cancer	0.00428	0.00444	CcSEcCtD
Cisatracurium Besylate—Angioedema—Sunitinib—kidney cancer	0.00427	0.00443	CcSEcCtD
Cisatracurium Besylate—Hypotension—Everolimus—kidney cancer	0.00426	0.00443	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Gemcitabine—kidney cancer	0.00423	0.00439	CcSEcCtD
Cisatracurium Besylate—Hypertension—Sorafenib—kidney cancer	0.00419	0.00435	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Vincristine—kidney cancer	0.00412	0.00427	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—kidney cancer	0.0041	0.00426	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Vincristine—kidney cancer	0.00409	0.00424	CcSEcCtD
Cisatracurium Besylate—Pruritus—Pazopanib—kidney cancer	0.00409	0.00424	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Everolimus—kidney cancer	0.00407	0.00422	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Capecitabine—kidney cancer	0.00406	0.00422	CcSEcCtD
Cisatracurium Besylate—Convulsion—Sunitinib—kidney cancer	0.00404	0.0042	CcSEcCtD
Cisatracurium Besylate—Hypertension—Sunitinib—kidney cancer	0.00403	0.00418	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Sorafenib—kidney cancer	0.00396	0.00411	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Sunitinib—kidney cancer	0.00395	0.0041	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Erlotinib—kidney cancer	0.00392	0.00407	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Gemcitabine—kidney cancer	0.0039	0.00405	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Gemcitabine—kidney cancer	0.00389	0.00404	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Sorafenib—kidney cancer	0.00388	0.00403	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Gemcitabine—kidney cancer	0.00388	0.00403	CcSEcCtD
Cisatracurium Besylate—Rash—Temsirolimus—kidney cancer	0.00387	0.00401	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Temsirolimus—kidney cancer	0.00386	0.00401	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Sorafenib—kidney cancer	0.00385	0.00399	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Capecitabine—kidney cancer	0.00377	0.00391	CcSEcCtD
Cisatracurium Besylate—Erythema—Gemcitabine—kidney cancer	0.00375	0.00389	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Sunitinib—kidney cancer	0.00374	0.00388	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Sunitinib—kidney cancer	0.0037	0.00384	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Paclitaxel—kidney cancer	0.00367	0.00381	CcSEcCtD
Cisatracurium Besylate—Rash—Pazopanib—kidney cancer	0.00364	0.00378	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Pazopanib—kidney cancer	0.00364	0.00378	CcSEcCtD
Cisatracurium Besylate—Bronchospasm—Capecitabine—kidney cancer	0.00363	0.00377	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Paclitaxel—kidney cancer	0.00354	0.00368	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Sorafenib—kidney cancer	0.00353	0.00367	CcSEcCtD
Cisatracurium Besylate—Convulsion—Vincristine—kidney cancer	0.00342	0.00355	CcSEcCtD
Cisatracurium Besylate—Hypertension—Vincristine—kidney cancer	0.00341	0.00354	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Sunitinib—kidney cancer	0.0034	0.00353	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vinblastine—kidney cancer	0.00337	0.0035	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Everolimus—kidney cancer	0.00336	0.00349	CcSEcCtD
Cisatracurium Besylate—Flushing—Paclitaxel—kidney cancer	0.00334	0.00347	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Paclitaxel—kidney cancer	0.00327	0.00339	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Paclitaxel—kidney cancer	0.00325	0.00338	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Paclitaxel—kidney cancer	0.00325	0.00337	CcSEcCtD
Cisatracurium Besylate—Hypertension—Gemcitabine—kidney cancer	0.00323	0.00336	CcSEcCtD
Cisatracurium Besylate—Pruritus—Everolimus—kidney cancer	0.00323	0.00335	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Vincristine—kidney cancer	0.00322	0.00335	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Gemcitabine—kidney cancer	0.00317	0.00329	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Vincristine—kidney cancer	0.00316	0.00328	CcSEcCtD
Cisatracurium Besylate—Urticaria—Sorafenib—kidney cancer	0.00315	0.00327	CcSEcCtD
Cisatracurium Besylate—Erythema—Paclitaxel—kidney cancer	0.00314	0.00326	CcSEcCtD
Cisatracurium Besylate—Pruritus—Erlotinib—kidney cancer	0.00311	0.00323	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Gemcitabine—kidney cancer	0.00306	0.00317	CcSEcCtD
Cisatracurium Besylate—Hypotension—Vincristine—kidney cancer	0.00301	0.00313	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Capecitabine—kidney cancer	0.00301	0.00312	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Gemcitabine—kidney cancer	0.003	0.00311	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Gemcitabine—kidney cancer	0.00297	0.00308	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Sorafenib—kidney cancer	0.00292	0.00303	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Capecitabine—kidney cancer	0.00291	0.00302	CcSEcCtD
Cisatracurium Besylate—Rash—Everolimus—kidney cancer	0.00288	0.00299	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Everolimus—kidney cancer	0.00287	0.00298	CcSEcCtD
Cisatracurium Besylate—Angioedema—Paclitaxel—kidney cancer	0.00287	0.00298	CcSEcCtD
Cisatracurium Besylate—Hypotension—Gemcitabine—kidney cancer	0.00286	0.00297	CcSEcCtD
Cisatracurium Besylate—Anaphylactoid reaction—Doxorubicin—kidney cancer	0.00285	0.00296	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Sunitinib—kidney cancer	0.00281	0.00291	CcSEcCtD
Cisatracurium Besylate—Pruritus—Sorafenib—kidney cancer	0.0028	0.00291	CcSEcCtD
Cisatracurium Besylate—Rash—Erlotinib—kidney cancer	0.00278	0.00288	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Erlotinib—kidney cancer	0.00277	0.00288	CcSEcCtD
Cisatracurium Besylate—Flushing—Capecitabine—kidney cancer	0.00274	0.00285	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Gemcitabine—kidney cancer	0.00273	0.00283	CcSEcCtD
Cisatracurium Besylate—Convulsion—Paclitaxel—kidney cancer	0.00272	0.00282	CcSEcCtD
Cisatracurium Besylate—Hypertension—Paclitaxel—kidney cancer	0.00271	0.00281	CcSEcCtD
Cisatracurium Besylate—Pruritus—Sunitinib—kidney cancer	0.0027	0.0028	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Capecitabine—kidney cancer	0.00268	0.00279	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Capecitabine—kidney cancer	0.00267	0.00277	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Capecitabine—kidney cancer	0.00266	0.00277	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Dactinomycin—kidney cancer	0.00266	0.00276	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—kidney cancer	0.00265	0.00275	CcSEcCtD
Cisatracurium Besylate—Cardiac arrest—Doxorubicin—kidney cancer	0.00262	0.00272	CcSEcCtD
Cisatracurium Besylate—Erythema—Capecitabine—kidney cancer	0.00257	0.00267	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Paclitaxel—kidney cancer	0.00256	0.00266	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Paclitaxel—kidney cancer	0.00251	0.00261	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Paclitaxel—kidney cancer	0.0025	0.00259	CcSEcCtD
Cisatracurium Besylate—Rash—Sorafenib—kidney cancer	0.0025	0.00259	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Sorafenib—kidney cancer	0.00249	0.00259	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Paclitaxel—kidney cancer	0.00249	0.00258	CcSEcCtD
Cisatracurium Besylate—Muscular weakness—Doxorubicin—kidney cancer	0.00243	0.00252	CcSEcCtD
Cisatracurium Besylate—Rash—Sunitinib—kidney cancer	0.0024	0.00249	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Sunitinib—kidney cancer	0.0024	0.00249	CcSEcCtD
Cisatracurium Besylate—Hypotension—Paclitaxel—kidney cancer	0.00239	0.00248	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Vincristine—kidney cancer	0.00237	0.00247	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Paclitaxel—kidney cancer	0.00228	0.00237	CcSEcCtD
Cisatracurium Besylate—Rash—Dactinomycin—kidney cancer	0.00227	0.00236	CcSEcCtD
Cisatracurium Besylate—Hypertension—Capecitabine—kidney cancer	0.00222	0.00231	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—kidney cancer	0.00218	0.00226	CcSEcCtD
Cisatracurium Besylate—Pruritus—Gemcitabine—kidney cancer	0.00216	0.00225	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Capecitabine—kidney cancer	0.00206	0.00214	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Capecitabine—kidney cancer	0.00205	0.00213	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Capecitabine—kidney cancer	0.00204	0.00212	CcSEcCtD
Cisatracurium Besylate—Urticaria—Paclitaxel—kidney cancer	0.00203	0.00211	CcSEcCtD
Cisatracurium Besylate—Rash—Vincristine—kidney cancer	0.00203	0.00211	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Vincristine—kidney cancer	0.00203	0.00211	CcSEcCtD
Cisatracurium Besylate—Hypotension—Capecitabine—kidney cancer	0.00196	0.00204	CcSEcCtD
Cisatracurium Besylate—Bradycardia—Doxorubicin—kidney cancer	0.00194	0.00201	CcSEcCtD
Cisatracurium Besylate—Rash—Gemcitabine—kidney cancer	0.00193	0.002	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Gemcitabine—kidney cancer	0.00193	0.002	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Paclitaxel—kidney cancer	0.00189	0.00196	CcSEcCtD
Cisatracurium Besylate—Connective tissue disorder—Doxorubicin—kidney cancer	0.00187	0.00194	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Capecitabine—kidney cancer	0.00187	0.00194	CcSEcCtD
Cisatracurium Besylate—Pruritus—Paclitaxel—kidney cancer	0.00181	0.00188	CcSEcCtD
Cisatracurium Besylate—Flushing—Doxorubicin—kidney cancer	0.00177	0.00184	CcSEcCtD
Cisatracurium Besylate—Angiopathy—Doxorubicin—kidney cancer	0.00173	0.0018	CcSEcCtD
Cisatracurium Besylate—Immune system disorder—Doxorubicin—kidney cancer	0.00172	0.00179	CcSEcCtD
Cisatracurium Besylate—Mediastinal disorder—Doxorubicin—kidney cancer	0.00172	0.00178	CcSEcCtD
Cisatracurium Besylate—Urticaria—Capecitabine—kidney cancer	0.00167	0.00173	CcSEcCtD
Cisatracurium Besylate—Erythema—Doxorubicin—kidney cancer	0.00166	0.00172	CcSEcCtD
Cisatracurium Besylate—Rash—Paclitaxel—kidney cancer	0.00161	0.00168	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Paclitaxel—kidney cancer	0.00161	0.00167	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Capecitabine—kidney cancer	0.00155	0.00161	CcSEcCtD
Cisatracurium Besylate—Pruritus—Capecitabine—kidney cancer	0.00149	0.00154	CcSEcCtD
Cisatracurium Besylate—Convulsion—Doxorubicin—kidney cancer	0.00144	0.00149	CcSEcCtD
Cisatracurium Besylate—Hypertension—Doxorubicin—kidney cancer	0.00143	0.00149	CcSEcCtD
Cisatracurium Besylate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—kidney cancer	0.0014	0.00146	CcSEcCtD
Cisatracurium Besylate—Anaphylactic shock—Doxorubicin—kidney cancer	0.00135	0.00141	CcSEcCtD
Cisatracurium Besylate—Nervous system disorder—Doxorubicin—kidney cancer	0.00133	0.00138	CcSEcCtD
Cisatracurium Besylate—Rash—Capecitabine—kidney cancer	0.00132	0.00138	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Capecitabine—kidney cancer	0.00132	0.00137	CcSEcCtD
Cisatracurium Besylate—Tachycardia—Doxorubicin—kidney cancer	0.00132	0.00137	CcSEcCtD
Cisatracurium Besylate—Skin disorder—Doxorubicin—kidney cancer	0.00132	0.00137	CcSEcCtD
Cisatracurium Besylate—Hypotension—Doxorubicin—kidney cancer	0.00127	0.00131	CcSEcCtD
Cisatracurium Besylate—Dyspnoea—Doxorubicin—kidney cancer	0.00121	0.00125	CcSEcCtD
Cisatracurium Besylate—Urticaria—Doxorubicin—kidney cancer	0.00108	0.00112	CcSEcCtD
Cisatracurium Besylate—Hypersensitivity—Doxorubicin—kidney cancer	0.000998	0.00104	CcSEcCtD
Cisatracurium Besylate—Pruritus—Doxorubicin—kidney cancer	0.000958	0.000995	CcSEcCtD
Cisatracurium Besylate—Rash—Doxorubicin—kidney cancer	0.000854	0.000886	CcSEcCtD
Cisatracurium Besylate—Dermatitis—Doxorubicin—kidney cancer	0.000853	0.000886	CcSEcCtD
